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HIV-1-infected people have an increased risk of developing extrapulmonary tuberculosis
(TB), the immunopathogenesis of which is poorly understood. Here, we conducted a
detailed immunological analysis of human pericardial TB, to determine the effect of HIV-1
co-infection on the phenotype of Mycobacterium tuberculosis (MTB)-specific memory T cells
and the role of polyfunctional T cells at the disease site, using cells from pericardial fluid
and blood of 74 patients with (n550) and without (n524) HIV-1 co-infection. The MTB
antigen-induced IFN-c response was elevated at the disease site, irrespective of HIV-1
status or antigenic stimulant. However, the IFN-c ELISpot showed no clear evidence of
increased numbers of antigen-specific cells at the disease site except for ESAT-6 in HIV-1
uninfected individuals (p50.009). Flow cytometric analysis showed that CD41 memory
T cells in the pericardial fluid of HIV-1-infected patients were of a less differentiated
phenotype, with the presence of polyfunctional CD41 T cells expressing TNF, IL-2 and
IFN-c. These results indicate that HIV-1 infection results in altered phenotype and function
of MTB-specific CD41 T cells at the disease site, which may contribute to the increased risk
of developing TB at all stages of HIV-1 infection.
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Introduction
Persons with human immunodeficiency virus (HIV-1) infection
are at an increased risk of developing tuberculosis (TB),
especially extrapulmonary TB [1, 2]. It is important to under-
stand the development of extrapulmonary TB, as its pathogenesis
differs from pulmonary disease [3, 4]. Little is known about
lymphocyte recruitment, the immunological response, or the
effect of HIV-1 infection on the immunopathogenesis at disease
sites of extrapulmonary TB.
Mycobacterium tuberculosis (MTB) infection of the peri-
cardium results in accumulation of fluid around the heart, or
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fibrosis of the pericardium, with a high mortality rate [5]. Peri-
cardial effusions are generally lymphocytic with CD41 T cells
dominating in HIV-1 uninfected and CD81 T cells in HIV-1-
infected pericardial TB patients [6]. However, the detailed
phenotype of T cells at the disease site has never been investi-
gated.
Distinct memory T-cell populations in humans can be
phenotypically characterized using the combination of markers
such as CCR7, CD62L, CD45RA, CD27 and CD28 [7–10]. We
have previously shown that the antigen-specific T cells at the
disease site in pleural TB are predominantly CD41, able to exert
effector function rapidly (by releasing IFN-g within 6 h after
antigen contact), and lack the chemokine receptor CCR7 [11]. It
is not known, however, how HIV-1 co-infection affects the
phenotype of MTB-specific memory T cells at the disease site. It
has been shown that HIV-1 infection can affect the phenotype of
CD41 T cells specific for cytomegalovirus (CMV) in the blood of
persons co-infected with HIV-1 and CMV towards a less differ-
entiated state [12]. This finding suggests that HIV-1 infection
affects the phenotype of CD41 T cells specific for other patho-
gens, resulting in reduced ability of the immune system to control
other, co-infecting pathogens, and thereby opportunistic infec-
tions.
CD41 T cells secreting IFN-g play an essential role in protec-
tive immunity against TB [13]. However, the recent evidence
suggests that polyfunctional CD41 T cells secreting IFN-g in
combination with other cytokines, such as tumor necrosis factor
(TNF) and interleukin (IL)-2, may also contribute [14–25]. These
cells can be found in the blood of HIV-1-infected people, but their
ability to secrete more than one cytokine decreases with
increasing HIV-1 viral load [26]. The polyfunctionality of blood
CD41 T cells specific for MTB is restored by antiretroviral treat-
ment [27]. HIV-1 infection severely impairs the frequency of
polyfunctional cells in the bronchoalveolar lavage of people with
latent TB [28], but whether these T cells are present at TB disease
sites, or what effect HIV-1 co-infection has, is not known.
Here, we describe the effect of HIV-1 co-infection on extra-
pulmonary TB in patients with pericardial TB. We specifically
determined the effect of HIV-1 on the phenotype of MTB-specific
memory cells at the disease site, as well as the role of polyfunc-
tional T cells at the disease site. We found that HIV-1 infection
results in altered phenotype and function of MTB-specific CD41
T cells at the site of disease towards a less differentiated and more
polyfunctional phenotype. These differences may relate to the
increased susceptibility to TB at all stages of HIV-infection.
Results
Characterization of pericardial TB patients at baseline
A total of 24 HIV-1-uninfected and 50 HIV-1-infected patients
with probable or definite pericardial TB were included in this
study. The baseline characteristics of the patients are summarized
in Table 1. HIV-1-infected patients presented with TB pericarditis
at a much younger age (median: 31; range: 20–66), compared
with the HIV-1-uninfected patients (median: 54: range: 19–80:
po0.0001). There was no difference in gender and TB diagnosis
classification (definite/probable) between HIV-1-uninfected and
infected patients. In the HIV-1-infected patients with available
CD41 counts (n538), the median was 109 (IQR 76–278)
cells/mL. CD41 count information was also available for 18
HIV-uninfected patients, with a median of 439 (IQR: 340–649),
significantly higher than the HIV-infected group (po0.0001). One
HIV-1-infected patient was taking antiretroviral treatment of two
weeks’ duration at the time of diagnosis.
Increased IFN-c secretion in pericardial fluid compared
with blood, irrespective of HIV-1 status
First, we compared the IFN-g secretion of whole blood and
pericardial fluid stimulated overnight with MTB-specific antigens
in 15 HIV-1-uninfected and 41 HIV-1-infected patients (Fig. 1).
The median concentration of IFN-g was significantly higher in the
unstimulated pericardial fluid compared with that in blood in
both groups of patients (1.2 ng/mL IQR 0–3.9 and 0.8 ng/mL IQR
0.1–3.6 in HIV-1-uninfected and infected pericardial fluid
respectively, both pr0.001 compared with blood). Stimulation
with MTB-specific antigens ESAT-6 and CFP-10 resulted in
further increase, to 6.2 ng/mL (IQR: 0.0–11.0) and 3.6 ng/mL
(IQR: 0.0–10.6) in the HIV-1-uninfected; and 2.7 ng/mL
Table 1. Characteristics of the patients included in the study
HIV-1 uninfected HIV-1 infected p-Valuea)
Number 24 50
Age (range) years 54 (19–80) 31 (20–66) po0.0001
Gender: Male/Female 18/6 28/22 p50.13
TB diagnosis: definite/probable 14/10 26/24 p50.63
CD4 count (IQR) 439 (340–649) [n5 18] 109 (76–278) [n5 38] po0.0001b)
Number on anti retroviral treatment n/a 1 N/a
a) Indicating differences between the HIV-1-uninfected and infected groups of patients, using Fisher’s exact test.
b) CD4 counts between the HIV-1-uninfected and infected groups were compared using the Mann–Whitney U test.
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(IQR: 0.25–8.4) and 2.5 ng/mL (IQR: 0.25–8.3) in HIV-1-infected
pericardial fluid respectively (pr0.002 when compared with
blood, Fig. 1). Although IFN-g concentrations in the pericardial
fluid of HIV-1-uninfected patients tended to be higher, a similar
increase in response to antigen stimulation occurred in both HIV-
1-infected and uninfected patient groups, with no statistically
significant difference between them.
Increased ESAT-6 specific IFN-c-producing cell
numbers in HIV-1-uninfected pericardial fluid
We hypothesized that the increased concentration of IFN-g at the
disease site would relate to increased numbers of antigen-
secreting cells. Using the ELISpot assay with PBMCs and
pericardial fluid cells (PFCs) of 9 HIV-1-uninfected and 23
HIV-1-infected patients, the frequency of IFN-g-producing cells at
the disease site compared with that in blood was determined
(Fig. 2). ELISpot responses were detectable in both blood and
pericardial fluid, but there was no clear evidence of increased
numbers of antigen-specific cells at the disease site with
significant heterogeneity between patients in response to all
antigenic stimulants (Fig. 2 and Supporting Information Fig. 1).
Comparing HIV-1 infected patients with uninfected controls, the
only significant difference was the response to ESAT-6 in
pericardial fluid, with a median of 10 SFC/106 in HIV-1-infected
patients compared with 195 SFC/106 in HIV-1-uninfected
patients (p50.009).
Increased numbers of CD41 T cells at the disease site
of HIV-1-uninfected patients
The trends towards lower numbers of antigen-specific T cells at
the disease site in HIV-1-infected patients, together with the
lower concentrations of secreted IFN-g suggested that HIV-1
decreases the T-cell responses at the site of disease. To evaluate
this further, we employed 4- and 8-colour flow cytometry to
determine the surface phenotype and cytokine secretion of
pericardial T cells. Supporting Information Figs. 2 and 3 illustrate
the gating strategies.
Figure 1. Pericardial TB patients have increased antigen-specific IFN-g
secretion in the pericardial fluid compared with blood. Undiluted blood
and pericardial fluid were cultured overnight either unstimulated (NIL)
or stimulated with ESAT-6 and CFP-10. IFN-g concentration (ng/mL)
was determined by ELISA and bars represent medians. Each circle is
representative of one sample. P-Values indicate the differences
between blood and pericardial fluid using the Wilcoxon-matched pairs
test.
Figure 2. Increased numbers of ESAT-6-specific IFN-g-producing cells in the pericardial fluid of HIV-1-uninfected patients. PBMCs and PFCs were
assessed for antigen-specific IFN-g responses by ELISpot assay. Each circle represents the number of IFN-g spot forming cells/106 cells in response
to ESAT-6 and CFP-10, corrected for unstimulated control wells. The number of ESAT-6 specific IFN-g spot forming cells/106 cells was significantly
higher in the pericardial fluid of the HIV-1-uninfected patients compared with HIV-1-infected patients (p5 0.009, Mann–Whitney U test).
Eur. J. Immunol. 2012. 42: 147–157 Immunity to infection 149
& 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Four-colour FACS on PBMCs and PFCs from 8 HIV-1-unin-
fected and 9 HIV-1-infected patients demonstrated an increased
proportion of CD31 lymphocytes in the pericardial fluid
compared with blood in HIV-1 uninfected patients (median
86.9% IQR 72.6–90.5 versus 53.3% IQR 29.6–76.6, respectively,
p50.021, Table 2). In contrast, HIV-1-infected patients showed
no significant difference between the proportions or numbers of
CD31 lymphocytes in blood and pericardial fluid.
Next, we assessed CD41 and CD81 T cells in the pericardium
and found a shift from a predominantly CD41 phenotype in the
HIV-1-uninfected patients, towards a predominantly CD81
phenotype in the HIV-1 infected. Thus, the median ratio of peri-
cardial CD41 to CD81 T-cell proportions in HIV-1-uninfected
patients was 1.71, and in the HIV-1-infected patients 0.66. This
was reflected in significantly higher CD41 T-cell numbers in the
pericardial fluid compared with blood in HIV-1-uninfected patients
(p50.023, Table 2). These data support the previous finding that
the predominant T cells are CD41 in the pericardial effusion of
HIV-1-uninfected patients, whereas CD81 T cells are predominant
in the pericardial effusions of HIV-1-infected patients [6].
Since HIV-1 infection causes generalized immune activation
[29], we evaluated cell surface expression of HLA-DR and the
transferrin receptor CD71 that represent activated and prolifer-
ating T cells [30]. While there was no significant difference in the
proportion of HLA-DR positive cells between blood and disease
site in either patient group, proliferating CD41CD711 T cells
were proportionally expanded (median: 11.2%; IQR: 7.2–32) in
the pericardial fluid of the HIV-1-infected patients compared with
blood (7.6%; IQR: 3–11.9; p50.023, Table 2).
NK cells also produce IFN-g in response to pathogens [31]. We
therefore hypothesized that CD3CD161CD561 cells would be
over-represented at the site of disease of HIV-infected patients.
However, no significant difference between blood (median:
6.2%; IQR: 2.6–27) and disease site (6.4%; IQR: 0.7–19.9) was
found; while in the HIV-1 uninfected patients NK cells were
significantly lower at the site of disease compared with blood
(median 1.7% IQR 0.04–6.7, and 14.1% IQR 6.4–27.1, respec-
tively, p50.035, Table 2). The greater proportion of NK cells in
the pericardial fluid of the HIV-1-infected patients (although not
significant) indicates that a proportion of IFN-g produced at the
site of disease originates from these cells.
CD41 memory T cells in the pericardial fluid of HIV-1-
infected patients are less differentiated
We hypothesized that the memory phenotype of CD41 T cells
present at the disease site of HIV-1-infected patients would
be different from that of uninfected patients, contributing
to the differences we have described. First, we used 4-colour
FACS with the combination of CD45RA and CD28 to characterize
the memory phenotype of CD41 T cells in pericardial fluid [9].
We found significantly higher proportions of the less
differentiated CD281CD45RA CD41 T cells in the pericardial
fluid of HIV-1-infected patients (56.0%; IQR: 39.2–77.6)
compared with HIV-1-uninfected patients (30.87%; IQR:
8.7–55.6; p50.04, Fig. 3A).
Next, we employed multiparameter FACS for in-depth pheno-
typic analysis of CD41 memory T cells in the pericardium of addi-
tional 10 HIV-1-uninfected and 9 HIV-1-infected patients (Fig. 3B).
We found that the majority of CD41 T cells at the disease site of
HIV-1-infected patients did not display the disease site homing
CCR5 receptor, with the dominant phenotype being
CD45RACD27CCR5 (median: 47.2%; IQR: 21.7–71.2), signifi-
cantly higher than in HIV-1-uninfected patients (median: 14.8%;
IQR: 3.9–37.7; p50.02). Similarly, terminally differentiated
CD45RA1CD271CCR51 CD41 T cells were infrequent in the peri-
cardial fluid of HIV-1-infected patients (median of 2.2% IQR 1–6.7),
compared with 10.3% (IQR: 1.3–36.1) in HIV-1-uninfected patients
(p50.012). Thus, our data suggest, that HIV-1-infection may
eliminate the CCR51memory T cells, resulting in the recruitment of
less differentiated memory T cells to the disease sites.
Increased cytokine secreting capacity at the disease
site irrespective of HIV-1 status
Since the differentiation status of memory T cells affects their
overall cytokine secreting capacity, we next investigated the CD41
T cells in the pericardium that express IFN-g, IL-2, TNF, IL-17 and
GM-CSF, in response to antigen-specific stimulation (Fig. 4 and
Supporting Information Fig. 4). There was a trend towards a higher
proportion of cytokine expressing cells in the pericardial fluid
compared with blood, significant in HIV-1-infected patients, with
higher proportions of IL-2 (median 1.37% in fluid versus 0.01% in
blood, p50.03), TNF (1.02% in fluid versus 0.11% in blood,
p50.03), and IL-171 cells (0.36% in fluid versus 0.01% in blood,
p50.03). These results are congruent with the presence of less
differentiated cells at the disease site of the HIV-1-infected patients.
Polyfunctionality of CD41 T cells in pericardial fluid
We next determined the presence of CD41 T cells expressing
combinations of IFN-g, IL-2 and TNF, that have been described in
the blood of TB patients and healthy controls vaccinated with
novel TB vaccines [14], but have not been hitherto assessed at TB
disease sites. We found no CD41 T cells expressing all three
cytokines in response to hkH37Rv or ESAT-61CFP-10 in the
blood, and very low proportions in the pericardial fluid of the
HIV-1-uninfected patients (Fig. 5A and C). The majority of
antigen-specific cells was single positive for IFN-g or TNF, or
expressed both IFN-g and TNF.
In the HIV-1-infected group (Fig. 5B) there was more antigen-
specific heterogeneity compared with the HIV-1-uninfected
patients. Thus, in response to hkH37Rv, the majority of antigen-
specific cells were single positive for IFN-g, followed by cells
double positive for IFN-g and TNF. In response to ESAT-61CFP-
10 stimulation, the majority of cells were IL-2 single positive
(p50.024 compared with HIV-1 uninfected), followed by TNF
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single positive, and IFN-g single positive. Interestingly, CD41
T cells expressing all three cytokines were present in the peri-
cardium only (Fig. 5C and Supporting Information Fig. 5). Thus,
the pericardial fluid of HIV-1-infected patients showed a greater
tendency towards polyfunctionality, consistent with the presence
of less differentiated cells.
HIV-1 viral load is increased in pericardial fluid
It has previously been suggested that HIV-1 replication is increased
at sites of MTB co-infection [32]. To assess viral replication at the
pericardial disease site, we determined HIV-1 viral load in paired
serum and cell-free pericardial fluid from 10 HIV-1-infected
patients. We found significantly increased HIV-1 viral load in the
pericardium (median 445000 copies/mL) compared with blood
(median 20500 copies/mL, p50.002, Fig. 6), with an inverse
correlation between the viral load and CD41 T-cell proportions
(Spearman R50.810, p50.022) at the site of disease. A
significant negative correlation between the memory cells most
prominently found at the disease site of the HIV-1-uninfected
patients (number of CD41CD28CD45RA cells/106 PFCs) and
pericardial viral load was also found (R50.76, p50.05). These
findings support that anatomically compartmentalized HIV-1 viral
replication at extrapulmonary TB disease sites may be responsible
for the skewed memory phenotype, possibly by local destruction of
the CCR51CD41 T cells.
Discussion
We have performed a detailed immunological investigation of
cells from patients infected with two pathogens, MTB and HIV-1.
By comparing blood and pericardial fluid from TB patients with
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Figure 3. Flow cytometric analysis of CD41 memory T cells in the
pericardial fluid. (A) PFCs from HIV-1-uninfected (n5 8, closed circles)
and HIV-1-infected (n5 7, open circles) patients were stimulated
overnight in the presence of hkH37Rv, followed by surface staining
for four-colour flow cytometry using CD41, CD45RA and the co-
stimulatory marker CD28. A significantly higher proportion of CD281
CD45RA cells at the disease site of the HIV-1-infected patients
(p5 0.04, Mann–Whitney U test), indicates a shift towards a less
differentiated memory phenotype. Bars represent medians. (B) PFCs
from HIV-1-uninfected (n5 8, closed circles) and HIV-1-infected (n5 10,
open circles) patients were stimulated overnight in the presence of
hkH37Rv, followed by surface staining for eight colour flow cytometry,
including CD3, CD4, CD45RA, the co-stimulatory marker CD27 as well
as CCR5 to phenotype the cells at the site of disease. The data indicate
that CD41 memory T cells in the pericardial fluid of HIV-1-infected
patients lack the CCR5 receptor. A significantly higher proportion of
CCR5CD27CD45RA cells (p5 0.02), and significantly fewer CCR51
CD271CD45RA1 cells (p5 0.012) were found at the disease site of HIV-1-
infected patients, compared with HIV-1-uninfected patients
(Mann–Whitney U test). Bars represent medians.
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Figure 4. Increased cytokine-secreting capacity in the pericardium
compared with that in blood, irrespective of HIV-1 status. Total
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and without HIV-1 infection, we show that the majority of CD41
T cells at the disease site of HIV-1-uninfected patients express
CCR5 and are of effector memory and terminally differentiated
phenotype. HIV-1 infection results in altered MTB-specific
memory CD41 T cells at the disease site towards a less
differentiated phenotype lacking the CCR5 receptor.
CCR5 is the chemokine co-receptor used by some strains of
HIV-1 to gain entry into the CD41 T cells. Using the simian
immunodeficiency virus (SIV) model, macaques infected with the
CCR5-tropic virus were unable to sustain the production of tissue
homing CCR51CD41 memory T cells [33]. Furthermore, it is
known that HIV-1 preferentially infects and depletes CD41
memory T cells, most of which are CCR51, and this can affect
lymphocyte trafficking to disease sites [34]. Here, we show that
the pericardium is a site of increased HIV-1 replication that could
further contribute to localized destruction of CCR51 cells. This
may result in greater overall turnover of memory T cells, of a less
differentiated phenotype. We speculate that in the absence of
CCR5, MTB-specific CD41 T cells use CXCR3 to migrate to the
disease site. The lack of evaluation of CXCR3 is a limitation of this
work, but the large amounts of CXCL10 detected in the peri-
cardial fluid (data not shown) support this hypothesis.
We and others have previously demonstrated greatly elevated
numbers of antigen-specific IFN-g-producing T cells at the TB
disease site using pleural fluid [11, 35], bronchoalveolar lavage
fluid [36] and cerebrospinal fluid [37]. Two case reports also
describe the rapid diagnosis of TB pericarditis using the ELISpot
assay [38, 39]. Surprisingly, we found that the IFN-g-specific
ELISpot in pericardial fluid showed no clear concentration of
antigen-specific IFN-g-secreting cells, except for ESAT-6 in the
case of HIV-1-uninfected patients. Compartmentalisation of
ESAT-6-specific IFN-g-secreting cells at the pericardial disease site
exclusively in HIV-1-uninfected patients reflects the presence of
more differentiated effector cells, congruent with our flow cyto-
metric findings, and may indicate the contribution of these cells
to host defense in containing MTB at sites of replication [11].
The ELISpot data were also surprising due to the apparent
dissociation from the ELISA results that indicated increased IFN-g
secretion in pericardial fluid compared with blood, irrespective of
HIV-1 status. This could be the result of the different detection
methods, since cells in the pericardial fluid release IFN-g and die,
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Figure 5. Polyfunctional CD41 T cells are present at the disease site.
CD31CD41 T cells were assessed for the expression of various
combinations of IFN-g, IL-2 and TNF in response to (A) hkH37Rv and
(B) ESAT-61CFP-10 stimulation, in the pericardial fluid of HIV-1-
uninfected (closed circles) and HIV-1-infected (open circles) patients.
(C) Pie-charts illustrate the overall proportional contribution of
cytokine expressing cells to the antigen-specific response in blood
and pericardial fluid. 11: any one cytokine, 21: any two cytokines, 31:
all three cytokines. IL-2 single-positive cells were proportionally
expanded in the HIV-1-infected pericardial fluid compared with the
uninfected in response to ESAT-61CFP-10 (B, p5 0.024, Mann–Whitney
U test).
Figure 6. HIV viral load is increased in pericardial fluid compared with
blood. HIV-1 RNA copies/mL were significantly elevated in matched
pericardial fluid compared with serum from HIV-1-infected patients
(p5 0.002, Wilcoxon-matched pairs test). Squares represent the patient
on ARV treatment at enrolment into the study.
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resulting in the accumulation of IFN-g measured by ELISA. The
ELISpot however, detects cells that produce IFN-g and are present
in the pericardial fluid at a given time (which is the time of
pericardiocentesis in this case) and thus it does not account for
the accumulated IFN-g.
Intracellular cytokine staining experiments also demonstrated
the potential of pericardial cells to secrete multiple cytokines
compared with PBMCs in both HIV-1-infected and uninfected
patients. Intracellular flow cytometry represents the effector
potential of the cells rather than the actual effector function,
since it stains cytokines intracellularly, only some of which would
be eventually secreted (and thus be detected by the ELISpot
assay). The fact that the difference was only significant in
HIV-infected patients (for IL-2, TNF and IL-17), agrees with the
less differentiated, more polyfunctional cytokine-secreting
phenotype of the cells present at the disease site of these patients.
Furthermore, increased IL-2 secretion was noted at the disease
site of the HIV-1-infected patients only, and IL-2 secretion is
characteristic of T cells with a less differentiated phenotype [9].
These findings taken together with significantly elevated
proportions of cycling (CD711) cells at the disease site of the
HIV-1-infected patients, support the presence of phenotypically
less differentiated T cells.
Polyfunctional T cells that secrete multiple cytokines, most
often studied as various combinations of IFN-g, IL-2 and TNF,
have recently been implicated as both a correlate of protection
and pathology in TB, highlighting the difficulties of evaluating
human immunity to TB [14]. Our data show that low proportions
of ESAT-61CFP-10-specific triple-positive T cells were detectable
at the disease site of both HIV-1-infected and uninfected patients.
The presence of polyfunctional CD41 T cells at the disease site of
HIV-1-infected patients is consistent with the less mature
phenotype of CD41 memory T cells at the disease site. However,
their presence at the disease site of the HIV-1-uninfected patients
may support the recent suggestion that TB antigen-specific
multifunctional T cells are better correlates of antigen load and
disease status, than of protection [40].
Immune responses seen at extrapulmonary disease sites may
be different from those seen in lung granulomas. A previous study
comparing radiographically involved lung segment biopsies of
pulmonary TB between HIV-1-infected and uninfected patients
found higher proportions of lymphocytes in the involved
segments of HIV-1-uninfected patients, together with lower
proportions of CD41 T cells in the HIV-1-infected patients [41].
We similarly described significantly higher CD31 lymphocyte
proportions and CD41 T-cell numbers at the disease site of HIV-1-
uninfected patients.
It is recognised that HIV-1 viral load and HIV-1 replication can
affect the maturation of CD41 T cells responding to other patho-
gens, such as CMV, towards an earlier, less differentiated state
which might adversely affect their ability to control those patho-
gens [12, 42]. Our data indicate that the same appears true in case
of MTB-specific CD41 T cells. The significantly elevated viral load
in the pericardial fluid compared with the blood further supports
the idea, that HIV-1 replication at the disease site results in the
presence of less differentiated cells, which may impair the ability of
the immune system to control MTB replication. Early anti-retro-
viral treatment could have an important role in preserving the
capacity of the immune system to control other pathogens.
Materials and methods
Patients
The University of Cape Town Faculty of Health Sciences Human
Research Ethics Committee approved this study (reference number
402/2005), and all participants provided written informed consent.
Patients with large pericardial effusions and suspected TB
pericarditis were referred to the Cardiac Clinic at Groote Schuur
Hospital, Cape Town, between February 2006 and December 2009.
Each patient underwent echocardiography to assess the presence
and size of pericardial effusion. When clinically indicated,
pericardiocentesis was performed under echocardiographic
guidance through a catheter. The case definition of pericardial TB
has previously been reported [43], with either definite (positive for
MTB complex in the pericardial fluid by culture or PCR) or
probable TB pericarditis (empirical diagnosis by the clinical team,
based on clinical signs, symptoms and response to TB treatment).
Counseling and testing for HIV-1 were inclusion criteria for the
study. Paired pericardial fluid and blood samples were collected
from 74 patients in total (24 were HIV-1 uninfected and 50 were
HIV-1 infected, Table 1). Due to limitation of cells available, not all
assays were performed on all samples.
Antigens
Antigenic stimuli were endotoxin-free and included the secreted
Region of Difference-1 (RD1) encoded ESAT-6 (Rv3875) and
CFP-10 (Rv3874) at a final concentration of 10mg/mL. Additional
antigens included a-crystallins Acr1 (Rv2031c) and Acr2
(Rv0251c), as well as the MTB cell wall-associated 38 kDa
antigen (Rv0934, all at 10 mg/mL) for the IFN-g ELISpot assay.
The heat-killed (hk) laboratory strain of MTB H37Rv was used to
stimulate cells for flow cytometry at a multiplicity of infection of
1 bacillus:1 cell (MOI5 1:1), in order to achieve a more robust
response. No antigenic stimulus was used as negative control,
while positive controls included phytohemagglutinin (PHA,
Sigma-Aldrich, 10 mg/mL), Purified Protein Derivative (PPD, SSI
Denmark, 5mg/mL) and staphylococcal enterotoxin B (SEB,
Sigma-Aldrich, 10 mg/mL) according to the assay.
Whole blood and pericardial fluid INF-c restimulation
assay
Undiluted pericardial fluid and whole blood obtained simulta-
neously were stimulated for 24 h with ESAT-6, CFP-10, PHA or no
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antigenic stimulus at 1mL/well in 24-well tissue culture plates.
Supernatant was removed and stored at 801C until measure-
ment of IFN-g by ELISA as previously described [44].
IFN-c ELISpot assay
ELISpot analysis was performed as previously described [45],
using cells from pericardial fluid and blood samples.
PBMCs were separated using Ficoll, while cells from the
pericardial fluid were isolated by centrifugation and washed
with RPMI. Totally, 2 105 cells in RPMI/10% FCS were
plated per well of pre-coated IFN-g MABTECH ELISpot plates.
Antigens, including ESAT-6, CFP-10, Acr1, Acr2, 38 kDa, PPD
were added at the doses described above, with PHA as the
positive control and no antigen as the negative control, followed
by incubation overnight (18 h) at 371C with 5% CO2. The results
are expressed as the number of antigen-specific spot forming cells
per million (SFC/106) corrected for the background (wells with
no antigen).
Flow cytometry and intracellular cytokine staining
assay
PBMCs and PFCs from pericardial TB patients were stimulated for
18 h with hkH37Rv, followed by staining for surface markers
including CD3-Allophycocyanin, CD4-Allophycocyanin, CD8-
PerCP, CD45RA-PE and FITC, CD71-PE, CD28-FITC, CD16-FITC,
CD56-PE and HLA-DR-FITC (all antibodies from BD Biosciences).
A BD-FACS Calibur Flow Cytometer was used to acquire all cells.
Isotype control antibodies and single stained samples were used
to periodically check the settings and gates on the flow cytometer.
Data analysis was performed using FlowJo Cytometry Analysis
software (TreeStar, Stanford University, FlowJo Africa scheme).
Additional experiments for intracellular cytokine staining
(ICS) combined with surface marker analysis, using an
8-colour panel were performed on a BD Biosciences
LSRII flow cytometer. Following stimulation with recombinant
ESAT-6 and CFP-10 (5mg/mL each), hkH37Rv, PPD, SEB as the
positive and no antigen as the negative controls, PBMCs and
PFCs were surface stained for CD4-QDot 605 (Invitrogen), CD3-
Pacific Blue, CD27-FITC, CCR5-PE, CD45RA-Allophycocyanin
(BD Biosciences) and intracellularly for IFN-g-AlexaFluor700
(eBioscience). Further cells were stained using CD4-QDot 605
(Invitrogen), CD3-Pacific Blue, IL-2-FITC (BD Biosciences), IFN-
g-AlexaFluor 700, IL-17-Alexa 647, GM-CSF-PE and TNF-PE Cy7
(eBioscience). Data analysis was performed with FlowJo Soft-
ware (Tree Star, Version 8.6.6 from FlowJo Africa, http://
www.flowjo.com/home/africa/) with Boolean gating to analyse
cells with multiple fluorescent markers. Background subtraction
was performed for all cytokine combination groups using the
unstimulated negative control to exclude non-specific cytokine
production. All negative values thus obtained were converted into
zero for further analysis.
Determination of HIV-1 viral load
Measurement of HIV-1 viral load was performed by the South
African National Health Laboratory Services (NHLS) at Groote
Schuur Hospital, using nucleic acid sequence-based amplification
(NASBA) on stored serum and cell-free pericardial fluid samples
from ten patients included in the FACS analysis experiments
described above. The limit of detection by this assay was 300
copies of HIV-1 RNA/mL sample.
Statistical analysis
Data were analysed using Graphpad Prism 5 Software (Graphpad
Software). The normality of samples was tested using D’Agostino
and Pearson omnibus normality test. Normally distributed paired
samples were compared by using a Student’s paired t-test, while
non-parametric paired samples were analysed using the Wilcoxon-
matched pairs test. Unpaired, non-parametric samples were tested
using the Mann–Whitney U test and unpaired, normally distributed
samples were compared using the unpaired Student’s t-test. A
p-value o0.05 was considered statistically significant. Data are
quoted as median (IQR) unless otherwise stated.
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